NASDAQ: GHRS - GH Research PLC

Yield per half year: +71.3%
Dividend yield: 0.00%
Sector: Healthcare

Share chart GH Research PLC

Extended chart Simple chart
Financial Markets by TradingView

About GH Research PLC

GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies to treat psychiatric and neurological disorders. The company develops 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable mebufotenin product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD.

more details
The company also develops GH002, an intravenous mebufotenin product candidate; and GH003, an intranasal mebufotenin product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2021-06-25
ISIN IE000GID8VI0
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.ghres.com
Цена ао 12.06
Change price per day: -6.45% (12.25)
Change price per week: -8.32% (12.5)
Change price per month: +4.47% (10.97)
Change price per 3 month: +60.96% (7.12)
Change price per half year: +71.3% (6.69)
Change price per year: +7.5% (10.66)
Change price per 3 year: -32.59% (17)
Change price per year to date: +60.96% (7.12)
All parameters

Underestimation

Title Value Grade
P/S 0 0
P/BV 2.04 7
P/E 0 0
EV/EBITDA -5.09 0
Total: 3.13

Efficiency

Title Value Grade
ROA, % -18.8 0
ROE, % -19.58 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.0153 10
Total: 9.2

Growth impulse

Title Value Grade
Yield Revenue, % 0 0
Yield Ebitda, % 13175.16 10
Yield EPS, % 4669.71 10
Total: 8
More

Institutions Volume Share, %
BVF Inc. 10400158 19.99
RA Capital Management, L.P. 5587333 10.74
RTW Investments LP 3327129 6.39
FMR, LLC 3136869 6.03
Lynx1 Capital Management Lp 1838617 3.53
VR Adviser, LLC 1318327 2.53
Verition Fund Management, LLC 1162485 2.23
Cormorant Asset Management, LP 593043 1.14
Deep Track Capital, LP 499400 0.96
5AM Venture Management, LLC 404404 0.78

ETFShare, %Profitability for 1 year, %Dividends, %
AdvisorShares Psychedelics ETF 4.2406 845.99 0.20
SPDR S&P International Small Cap ETF 0.01104 8.94 3.10348
2.13427.461.65



Head Job title Payment Year of birth
Mr. Florian Schonharting M.Sc. (Econ) Co-Founder & Non-Executive Chairman of the Board N/A 1969 (56 years)
Mr. Magnus Halle Co-Founder & MD of Ireland N/A 1997 (28 years)
Ms. Julie Ryan F.C.A. Vice President of Finance N/A 1986 (39 years)
Mr. Aaron Cameron M.B.A. Chief Operating Officer N/A 1985 (40 years)
Dr. Velichka Valcheva M.D. Chief Executive Officer N/A 1975 (50 years)

Address: Ireland, Dublin D RY, Joshua Dawson House - open in Google maps, open in Yandex maps
Website: https://www.ghres.com